{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:17:02Z","timestamp":1783052222084,"version":"3.54.6"},"reference-count":46,"publisher":"Impact Journals, LLC","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2019,7,9]]},"DOI":"10.18632\/oncotarget.27055","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T14:19:41Z","timestamp":1562681981000},"page":"4437-4448","source":"Crossref","is-referenced-by-count":10,"title":["Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancer"],"prefix":"10.18632","volume":"10","author":[{"given":"Laris","family":"Achlaug","sequence":"first","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rive","family":"Sarfstein","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Nagaraj","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Lapkina-Gendler","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Bruchim","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Division, Hillel Yaffe Medical Center, Affiliated with the Technion Institute of Technology, Haifa, Hadera 38100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Dixit","sequence":"additional","affiliation":[{"name":"David B. Kriser Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvi","family":"Laron","sequence":"additional","affiliation":[{"name":"Endocrine and Diabetes Research Unit, Schneider Children\u2019s Medical Center, Petah Tikva 49292, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoshana","family":"Yakar","sequence":"additional","affiliation":[{"name":"David B. Kriser Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haim","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel"},{"name":"Yoran Institute for Human Genome Research, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"1","first-page":"11","article-title":"Metabolic effects of IGF-I deficiency: lessons from mouse models","volume":"3","author":"Leroith","year":"2005","journal-title":"Pediatr Endocrinol Rev"},{"key":"2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/ncpendmet0427","article-title":"Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1","volume":"3","author":"Yakar","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"3","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tem.2006.06.007","article-title":"The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action","volume":"17","author":"Maor","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"4","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1007\/s00018-013-1514-y","article-title":"Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation","volume":"71","author":"Girnita","year":"2014","journal-title":"Cell Mol Life Sci"},{"key":"5","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1530\/ERC-11-0074","article-title":"Insulin receptor and cancer","volume":"18","author":"Malaguarnera","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/13813450902783106","article-title":"The insulin-like growth factor-I receptor as an oncogene","volume":"115","author":"Bruchim","year":"2009","journal-title":"Arch Physiol Biochem"},{"key":"7","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3215","article-title":"The insulin and insulin-like growth factor receptor family in neoplasia: an update","volume":"12","author":"Pollak","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1016\/S0140-6736(04)16044-3","article-title":"Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis","volume":"363","author":"Egger","year":"2004","journal-title":"Lancet"},{"key":"9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrendo.2010.171","article-title":"Growth hormone, the insulin-like growth factor axis, insulin and cancer risk","volume":"7","author":"Renehan","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1126\/science.279.5350.563","article-title":"Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study","volume":"279","author":"Pollak","year":"1998","journal-title":"Science"},{"key":"11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(97)10384-1","article-title":"Circulating concentrations of insulin-like growth factor-I and risk of breast cancer","volume":"351","author":"Pollak","year":"1998","journal-title":"Lancet"},{"key":"12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/ijc.11487","article-title":"The IGF-1 receptor in cancer biology","volume":"107","author":"Reiss","year":"2003","journal-title":"Int J Cancer"},{"key":"13","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.ghir.2014.03.006","article-title":"Transcriptional and epigenetic control of IGF1R gene expression: implications in metabolism and cancer","volume":"24","author":"Sarfstein","year":"2014","journal-title":"Growth Horm IGF Res"},{"key":"14","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3389\/fendo.2015.00106","article-title":"IGF-1 receptor and adhesion signaling: an important axis in determining cancer cell phenotype and therapy resistance","volume":"6","author":"O\u2019Connor","year":"2015","journal-title":"Front Endocrinol (Lausanne)"},{"key":"15","first-page":"152","article-title":"Genetic pituitary dwarfism with high serum concentation of growth hormone\u2014a new inborn error of metabolism?","volume":"2","author":"Mannheimer","year":"1966","journal-title":"Isr J Med Sci"},{"key":"16","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1210\/jc.2003-031033","article-title":"Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003","volume":"89","author":"Laron","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJM198910123211501","article-title":"Laron dwarfism and mutations of the growth hormone-receptor gene","volume":"321","author":"Goossens","year":"1989","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-11183-9","volume-title":"Laron Syndrome - From Man to Mouse","author":"Kopchik","year":"2011"},{"key":"19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.tem.2008.03.003","article-title":"IGF signaling defects as causes of growth failure and IUGR","volume":"19","author":"Kiess","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"20","doi-asserted-by":"publisher","first-page":"70ra13","DOI":"10.1126\/scitranslmed.3001845","article-title":"Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans","volume":"3","author":"Longo","year":"2011","journal-title":"Sci Transl Med"},{"key":"21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1530\/EJE-10-0859","article-title":"Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies","volume":"164","author":"Laron","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1530\/ERC-16-0054","article-title":"Identification of signaling pathways associated with cancer protection in Laron syndrome","volume":"23","author":"Werner","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0888-7543(95)80096-5","article-title":"Characterization of a large population of mRNAs from human testis","volume":"26","author":"Guella\u00ebn","year":"1995","journal-title":"Genomics"},{"key":"24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/molehr\/7.12.1115","article-title":"Meiotic human sperm cells express a leucine-rich homologue of Caenorhabditis elegans early embryogenesis gene, Zyg-11","volume":"7","author":"Guella\u00ebn","year":"2001","journal-title":"Mol Hum Reprod"},{"key":"25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/sj.embor.7400895","article-title":"The Caenorhabditis elegans cell-cycle regulator ZYG-11 defines a conserved family of CUL-2 complex components","volume":"8","author":"Kipreos","year":"2007","journal-title":"EMBO Rep"},{"key":"26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.201601083","article-title":"The ubiquitin ligase CRL2ZYG11 targets cyclin B1 for degradation in a conserved pathway that facilitates mitotic slippage","volume":"215","author":"Kipreos","year":"2016","journal-title":"J Cell Biol"},{"key":"27","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/oby.2008.228","article-title":"State ranks of incident cancer burden due to overweight and obesity in the United States, 2003","volume":"16","author":"Jemal","year":"2008","journal-title":"Obesity (Silver Spring)"},{"key":"28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Chan","year":"2006","journal-title":"Br J Cancer"},{"key":"30","first-page":"177","article-title":"p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis","volume":"150","author":"Hedrick","year":"1997","journal-title":"Am J Pathol"},{"key":"31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fendo.2014.00076","article-title":"The IGF hormonal network in endometrial cancer: functions, regulation, and targeting approaches","volume":"5","author":"Werner","year":"2014","journal-title":"Front Endocrinol (Lausanne)"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature","author":"Kyrgiou","year":"2018","journal-title":"Int J Cancer"},{"key":"33","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/sj.bjc.6601791","article-title":"Overexpression of HER-2\/neu in uterine serous papillary cancer","volume":"8","author":"Parham","year":"2002","journal-title":"Clin Cancer Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ejca.2011.09.014","article-title":"p53 Regulates insulin-like growth factor-I receptor gene expression in uterine serous carcinoma and predicts responsiveness to an insulin-like growth factor-I receptor-directed targeted therapy","volume":"48","author":"Werner","year":"2012","journal-title":"Eur J Cancer"},{"key":"35","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.4081\/tmr.6657","article-title":"Genome-wide profiling of congenital IGF1 deficient patients: translational implications in cancer prevention and metabolism","volume":"1","author":"Laron","year":"2017","journal-title":"Translational Medicine Reports"},{"key":"36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/0167-0115(93)90345-9","article-title":"Insulin-like growth factor regulation of human endometrial stromal cell function: coordinate effects on insulin-like growth factor binding protein-1, cell proliferation and prolactin secretion","volume":"48","author":"Giudice","year":"1993","journal-title":"Regul Pept"},{"key":"37","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1517\/14728222.2013.749863","article-title":"Targeting IGF-1 signaling pathways in gynecologic malignancies","volume":"17","author":"Werner","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ygyno.2011.01.008","article-title":"Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines","volume":"121","author":"Bruchim","year":"2011","journal-title":"Gynecol Oncol"},{"key":"39","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fonc.2016.00159","article-title":"Insulin-like growth factor 1 signaling axis meets p53 genome protection pathways","volume":"6","author":"Bruchim","year":"2016","journal-title":"Front Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"8247","DOI":"10.1073\/pnas.1431613100","article-title":"Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor","volume":"100","author":"Larsson","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"41","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1073\/pnas.93.16.8318","article-title":"Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene","volume":"93","author":"LeRoith","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"42","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1038\/onc.2011.447","article-title":"Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer","volume":"31","author":"Werner","year":"2012","journal-title":"Oncogene"},{"key":"43","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1073\/pnas.1715930115","article-title":"Identification of thioredoxin-interacting protein (TXNIP) as a downstream target for IGF1 action","volume":"115","author":"Werner","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"44","doi-asserted-by":"publisher","first-page":"8029","DOI":"10.18632\/oncotarget.6904","article-title":"ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"45","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/jbmr.1920","article-title":"Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor","volume":"28","author":"Yakar","year":"2013","journal-title":"J Bone Miner Res"},{"key":"46","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Schmittgen","year":"2001","journal-title":"Methods"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27055","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T18:48:52Z","timestamp":1596739732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.27055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":46,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2019,7,9]]}},"alternative-id":["27055","31320996"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.27055","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]}}}